Hui Shao

Hui Shao,

Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 294-8323
Business Email: hui.shao@ufl.edu

Teaching Profile

Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2021-2023
PHA6940 Supervised Teaching
2021-2022
PHA6971 Research for Master’s Thesis
2020-2022
PHA6935 Selected Topics in Pharmacy
2020-2023
PHA6910 Supervised Research
2021-2022
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2020-2023
PHA7979 Advanced Research
2021-2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2023
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2023
PHA6937 Topics in Pharmaceutical Administration
2020-2021
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm
2023
PHA6946 Practicum in the Pharmaceutical Sciences

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-4088-546X

Publications

2023
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States
Diabetes, Obesity and Metabolism. 25(10):2862-2868 [DOI] 10.1111/dom.15177.
2023
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism. 25(2):516-525 [DOI] 10.1111/dom.14894. [PMID] 36251173.
2023
Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Journal of managed care & specialty pharmacy. 29(8):884-895 [DOI] 10.18553/jmcp.2023.29.8.884. [PMID] 37523313.
2023
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
Journal of the American Geriatrics Society. 71(7):2096-2106 [DOI] 10.1111/jgs.18306. [PMID] 36821780.
2023
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Annals of Internal Medicine. 176(4):582-583 [DOI] 10.7326/m22-3051.
2022
A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial.
Journal of diabetes and its complications. 36(9) [DOI] 10.1016/j.jdiacomp.2022.108287. [PMID] 36007486.
2022
A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 25(8):1328-1335 [DOI] 10.1016/j.jval.2022.02.011. [PMID] 35367137.
2022
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Diabetes therapy : research, treatment and education of diabetes and related disorders. 13(9):1659-1670 [DOI] 10.1007/s13300-022-01300-5. [PMID] 35930188.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care. 45(11):e161-e162 [DOI] 10.2337/dc22-1230. [PMID] 36099174.
2022
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.
Journal of diabetes and its complications. 36(3) [DOI] 10.1016/j.jdiacomp.2022.108132. [PMID] 35101326.
2022
Growing global burden of type 1 diabetes needs multitiered precision public health interventions.
The lancet. Diabetes & endocrinology. 10(10):688-689 [DOI] 10.1016/S2213-8587(22)00257-1. [PMID] 36113506.
2022
Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative.
Current medical research and opinion. 38(11):1883-1884 [DOI] 10.1080/03007995.2022.2129234. [PMID] 36164760.
2022
Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.
Journal of the American Geriatrics Society. 70(9):2719-2722 [DOI] 10.1111/jgs.17895. [PMID] 35612586.
2022
Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes.
JAMA network open. 5(4) [DOI] 10.1001/jamanetworkopen.2022.7705. [PMID] 35435970.
2022
Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM‐CURE risk score
Diabetes, Obesity and Metabolism. 24(11):2203-2211 [DOI] 10.1111/dom.14806. [PMID] 35801340.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care. 45(8):1814-1821 [DOI] 10.2337/dc21-2601. [PMID] 35700384.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care. 45(2):e32-e33 [DOI] 10.2337/dc21-1800.
2022
Syndromic Surveillance Systems for Mass Gatherings: A Scoping Review.
International journal of environmental research and public health. 19(8) [DOI] 10.3390/ijerph19084673. [PMID] 35457541.
2022
Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model.
Journal of diabetes and its complications. 36(11) [DOI] 10.1016/j.jdiacomp.2022.108316. [PMID] 36201893.
2021
A varied approach to left ventricular assist device follow-up improves cost-effectiveness.
Current medical research and opinion. 37(9):1501-1505 [DOI] 10.1080/03007995.2021.1948395. [PMID] 34181489.
2021
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
Journal of diabetes and its complications. 35(9) [DOI] 10.1016/j.jdiacomp.2021.107972. [PMID] 34247911.
2021
Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer’s disease and related dementias (ADRD).
Current medical research and opinion. 37(10):1731-1737 [DOI] 10.1080/03007995.2021.1953972. [PMID] 34252317.
2021
Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 24(2):227-235 [DOI] 10.1016/j.jval.2020.09.010. [PMID] 33518029.
2021
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.
Current medical research and opinion. 37(11):1875-1880 [DOI] 10.1080/03007995.2021.1971181. [PMID] 34429001.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care. 44(10):e180-e182 [DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care. 44(4):925-934 [DOI] 10.2337/dc20-2871.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care. 43(2):e25-e25 [DOI] 10.2337/dc19-1891. [PMID] 31959647.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care. 43(10):2396-2402 [DOI] 10.2337/dc19-2273. [PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care. 43(11):2847-2852 [DOI] 10.2337/dc20-0465. [PMID] 32887705.
2020
Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults.
Journal of the American Heart Association. 9(24) [DOI] 10.1161/JAHA.120.018233. [PMID] 33317368.
2020
Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study.
Journal of clinical medicine. 9(8) [DOI] 10.3390/jcm9082332. [PMID] 32707877.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care. 43(7):1530-1536 [DOI] 10.2337/dc20-0227. [PMID] 32345650.
2019
Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 22(12):1402-1409 [DOI] 10.1016/j.jval.2019.08.007. [PMID] 31806197.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care. 42(11):2136-2142 [DOI] 10.2337/dc19-0381.

Grants

Sep 2022 – Dec 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022 – Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020 ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Project Manager
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020 – Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020 – Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV via SANOFI
Jun 2020 – Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION

Contact Details

Phones:
Business:
(352) 294-8323
Emails:
Business:
hui.shao@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
PO Box 100496
GAINESVILLE FL 32610

Recent news